Cargando…
870. Olorofim for the treatment of invasive mould infections in patients with limited or no treatment options: Comparison of interim results from a Phase 2B open-label study with outcomes in historical control populations (NCT03583164, FORMULA-OLS, Study 32)
BACKGROUND: Olorofim is a novel antifungal agent active against Aspergillus spp (including azole-resistant strains), rare, resistant moulds (e.g., Lomentospora prolificans) and dimorphic moulds. Serial images of Lomentospora prolificans infection following breast enhancement surgery: progression of...
Autores principales: | Maertens, Johan A, Verweij, Paul E, Lanuza, Evan F, Harvey, Emma L, Dane, Aaron, Zinzi, Daniela, Rex, John H, Chen, Sharon C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752288/ http://dx.doi.org/10.1093/ofid/ofac492.063 |
Ejemplares similares
-
In vitro activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including Penicillium and Talaromyces species
por: Singh, Ashutosh, et al.
Publicado: (2021) -
Resistance profiling of Aspergillus fumigatus to olorofim indicates absence of intrinsic resistance and unveils the molecular mechanisms of acquired olorofim resistance
por: Buil, Jochem B., et al.
Publicado: (2022) -
Review of the Novel Investigational Antifungal Olorofim
por: Wiederhold, Nathan P.
Publicado: (2020) -
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
por: Hoenigl, Martin, et al.
Publicado: (2021) -
Refractory Microascus Bronchopulmonary Infection Treated with Olorofim, France
por: Faure, Emmanuel, et al.
Publicado: (2023)